• Language
Customer Survey
Tell us about your project
Contact us to discuss how we can help you achieve your research goals
Clinical Panels

NovoPM™ 2.0

Comprehensive genomic profiling for 484 cancer-related genes to help you give the right treatment for your patients

The Novogene Precision Medicine 2.0 (NovoPM™ 2.0) comprehensive genomic profiling test for solid tumors is a next generation sequencing (NGS)-based assay that analyzes 484 genes for clinically important alterations at the DNA level. These genes are known to be relevant for the diagnosis and/or treatment of various solid tumors according to National Comprehensive Cancer Network (NCCN) Guidelines and the medical literature. All tests are performed in our CAP-accredited lab and analyzed by our in-house bioinformatics specialists. Report generated provides tailored treatment recommendations for your patients.

NovoPM™ 2.0 is developed based on NovoPM™ 1.0 with updated gene list and enhanced analytical performance.

Parameters

Novo™ 2.0
Cancer type Solid Tumors
Sample type Extracted DNA
FFPE
Whole blood
Blood Pasma
Extracted cDNA
Turnaround time ≤ 2 weeks
Novogene Quality Assurance
Comprehensive Gene Coverage For Herediatary Cancer Screening

Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes that are recommended by international guidelines

Advanced Technology

Using current state-of-art NGS technologies assess the SNP, InDel, and large fragment deletions at once

Authoritative Database

Integrated internationally recognized databases to interpret data and generate report

Competitive Price

With top tier sequencing capacity and excellent process efficiency, Novogene offers highly competitive prices for all our services

Who Benefits from NovoPM™ 2.0 ?
  • Individuals with advanced or late stage cancers.
  • Individuals who have tested negative for single gene mutations and require a more comprehensive tumor profiling.
  • Individuals with cancers of unknown primary origin.
  • Individuals with inadequate amount of tissue or unobtainable tissue for biopsy.
  • Individuals who may prefer non-invasive testing or are not suitable for invasive surgical procedure.

Gene Targets

NovoPM™ 2.0 interrogates the complete coding regions of 468 genes and the introns of 43 genes for all four types of genomic abnormalities: SNV, InDel, CNV and fusion. A comparison of the gene lists between NovoPM™ 2.0 and the FDA-approved FoundationOne CDx is shown in Figure 3. The mutation status of some of these genes can guide the potential application of multiple FDA-approved targeted and/or immunotherapies as shown in Table 1. The other genes are also analyzed for their relevance to the diagnosis and/or treatment of various solid tumors according to the medical literature. The clinical interpretation of detected mutations in those genes is done according to Novogene’s comprehensive in-house oncology knowledgebase constructed based on public resources including GeneCards, CKB, OncoKB, COSMIC, ClinVar PMC, Drugs@FDA, Drug Information Portal (NIH), Selleck, PharmGKB, DGIdb, DRUGBANK, Drugs.com, ClinicalTrials.gov, ICTRP, ChiCTR, KEGG and Cell Signaling. In addition, our oncology knowledgebase incorporates ~1,000 germline BRCA1/2 variants previously reported to be unique in Chinese breast cancer and ovarian cancer patients1.

Indication Biomarkers Biomarkers
Non-Small Cell Lung Cancer
EGFR 19Del and L858R Gilotrif® (afatinib), Iressa® (gefitinib) or Tarceva® (erlotinib)
EGFR T90M Tegrisso® (osimertinib)
ALK rearrangements Alecensa® (alectinib), Xalkori® (crizotinib), Zykadia® (ceritinib), Alunbrig® (brigatinib) or Lorbrena® (Lorlatinib)
BRAF V600E Tafinlar® (dabrafenib) + Mekinist® (trametinib)
ROS1 fusion Xalkori® (crizotinib) or Rozlytrek® (entrectinib)
TMB and bTMB Opdivo® (nivolumab), Keytruda® (pembrolizumab), or Tecentriq® (atezolizumab)
Melanoma BRAF V600E or V600k Tafinlar® (dabrafenib), Tafinlar® (dabrafenib) + Mekinist® (trametinib), Zelboraf® (vemurafenib) or Braftovi® (encorafenib) + Mektovi® (binimetinib)
Breast Cancer
ERBB2 (HER2) amplification Herceptin® (trastuzumab), Perjeta® (pertuzumab), Tykerb® (lapatinib) or Nerlynx (neratinib)
gBRCA alterations and ERBB2 (HER2) negative Talzenna® (talazoparib) or Lynparza® (olaparib)
PIK3CA alterations Piqray® (Alpelisib)
Colorectal Cancer
RAS wild-type Erbitux® (cetuximab), Vectibix® (panitumumab) or Stivarga® (regorafenib)
MSI-H Keytruda® (pembrolizumab), Opdivo® (nivolumab) or Opdivo® (nivolumab) + Yervoy® (ipilimumab)
Ovarian Cancer BRCA1 and BRCA2 alterations Lynparza® (olaparib) or Rubraca® (rucaparib)
Solid Tumors
MIS-H Keytruda® (pembrolizumab)
NTRK1/2/3 fusions Vitrakvi® (larotrectinib) or Rozlytrek® (entrectinib)

Sample requirement

Sample Type Sample Requirement
FFPE Approximately ten 4-µm sections, each with tissue area ≥ 25 mm2 and tumor content ≥ 20%.
Whole blood 10 mL (for ctDNA and white blood cell DNA extraction)
Blood Plasma 4 mL (for ctDNA extraction)

H3 Table with Data Intepretation

Positive Results Uncertain Variants Negative Results
Pathogenic/ Likely Pathogenic Uncertain Significant Variant Likely Benign/ Benign
Medical management based on recommendations for the specific variant Surveillance and medical management based on personal/family cancer history Recommendations based on general population cancer risk screening